BYSI
Beyondspring Inc
$
1.630
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.7583
Open
1.7583
VWAP
1.73
Vol
2.71K
Mkt Cap
65.72M
Low
1.630
Amount
4.69K
EV/EBITDA(TTM)
--
Total Shares
40.30M
EV
77.47M
EV/OCF(TTM)
--
P/S(TTM)
--
BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on using its technology platform for drug discovery and the development of therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.
Show More
Valuation Metrics
The current forward P/E ratio for Beyondspring Inc (BYSI.O) is -5.19, compared to its 5-year average forward P/E of -3.21. For a more detailed relative valuation and DCF analysis to assess Beyondspring Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.21
Current PE
-5.19
Overvalued PE
-0.92
Undervalued PE
-5.50
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-1.82
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.85
Undervalued EV/EBITDA
-4.49
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
34.27
Current PS
0.34
Overvalued PS
86.76
Undervalued PS
-18.22
Financials
Annual
Quarterly
FY2025Q1
0.00
Total Revenue
FY2025Q1
-2.61M
Operating Profit
FY2025Q1
-2.58M
Net Income after Tax
FY2025Q1
0.11
EPS - Diluted
FY2025Q1
-4.25M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
BYSI News & Events
Events Timeline
2025-03-27 (ET)
2025-03-27
07:11:56
BeyondSpring announces expected 2025 milestones
2025-03-27
07:11:04
BeyondSpring reports FY24 EPS (21c) vs. (34c) last year
2024-11-11 (ET)
2024-11-11
07:19:45
BeyondSpring presents efficacy results from Phase 2 IIT study of plinabulin
Sign Up For More Events
Sign Up For More Events
News
9.0
05-12NASDAQ.COMBeyondSpring Inc. Reports Positive Early Results for Plinabulin in Metastatic Cancer and Updates on SEED Therapeutics' Progress
9.5
05-12NewsfilterBeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
9.0
2024-11-11NewsfilterBeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
Sign Up For More News
People Also Watch
NB
NioCorp Developments Ltd
2.500
USD
+8.70%
ICCM
Icecure Medical Ltd
1.050
USD
0.00%
MGLD
Marygold Companies Inc
0.847
USD
-1.74%
ANVS
Annovis Bio Inc
2.640
USD
+12.34%
RMTI
Rockwell Medical Inc
0.996
USD
+1.32%
OAKU
Oak Woods Acquisition Corp
11.930
USD
0.00%
GNTA
Genenta Science SPA
4.490
USD
-0.22%
CULP
Culp Inc
4.170
USD
-1.88%
PRE
Prenetics Global Ltd
9.200
USD
-1.08%
FFIE
Faraday Future Intelligent Electric Inc
1.430
USD
+8.97%
FAQ
What is Beyondspring Inc (BYSI) stock price today?
The current price of BYSI is 1.63 USD — it has decreased -6.59 % in the last trading day.
What is Beyondspring Inc (BYSI)'s business?
What is the price predicton of BYSI Stock?
What is Beyondspring Inc (BYSI)'s revenue for the last quarter?
What is Beyondspring Inc (BYSI)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Beyondspring Inc (BYSI)'s fundamentals?
How many employees does Beyondspring Inc (BYSI). have?